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Purpose: To identify the molecular cause in five unrelated families
with a distinct autosomal dominant ocular systemic disorder we
called ROSAH syndrome due to clinical features of retinal dystrophy,
optic nerve edema, splenomegaly, anhidrosis, and migraine headache.
Methods: Independent discovery exome and genome sequencing
in families 1, 2, and 3, and confirmation in families 4 and 5.
Expression of wild-type messenger RNA and protein in human and
mouse tissues and cell lines. Ciliary assays in fibroblasts from
affected and unaffected family members.
Results: We found the heterozygous missense variant in the ɑ-
kinase gene, ALPK1, (c.710C>T, [p.Thr237Met]), segregated with
disease in all five families. All patients shared the ROSAH
phenotype with additional low-grade ocular inflammation, pancy-
topenia, recurrent infections, and mild renal impairment in some.
ALPK1 was notably expressed in retina, retinal pigment epithelium,
and optic nerve, with immunofluorescence indicating localization
to the basal body of the connecting cilium of the photoreceptors,
and presence in the sweat glands. Immunocytofluorescence
revealed expression at the centrioles and spindle poles during
metaphase, and at the base of the primary cilium. Affected family
member fibroblasts demonstrated defective ciliogenesis.
Conclusion: Heterozygosity for ALPK1, p.Thr237Met leads to
ROSAH syndrome, an autosomal dominant ocular systemic
disorder.
Genetics inMedicine (2019) 21:2103–2115; https://doi.org/10.1038/s41436-
019-0476-3
Keywords: retinal dystrophy; ALPK1; ROSAH syndrome; cilio-
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INTRODUCTION
Retinal dystrophy describes progressive degeneration or
abnormality of photoreceptors (rods and cones) leading to
vision loss, with a worldwide prevalence of approximately 1 in
3500 (ref. 1). Cases may be isolated or syndromic with a number
of additional organs involved. Syndromal forms include
metabolic conditions such as Refsum disease (MIM 266500),
storage disorders such as neuronal ceroid lipofuscinosis 3
(MIM 204200), and conditions where there are primary ciliary
abnormalities including Bardet–Biedl (MIM 209900),
Senior–Løken (MIM 266900), and Joubert syndromes (MIM
213300) (ref. 2). Each of these disorders has specific clinical and/
or laboratory features that facilitate diagnosis, and are usually
associated with autosomal recessive inheritance.
We previously described, in Tantravahi et al.,3 a family
with an autosomal dominant mode of inheritance of a
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unique constellation of ocular and systemic features that
presented to the ophthalmology and hematology clinics of
the University of Utah. The features common to all three
affected individuals in this family included a severe retinal
dystrophy of the cones and rods, optic nerve edema, mild
pancytopenia, and idiopathic massive splenomegaly. Two of
the affected individuals had anhidrosis and migraine
headaches, with one also experiencing episodic urticaria.
Despite extensive literature search and discussion with
colleagues, no other similarly affected individuals were
identified at that time.
Here, we describe the clinical features of four additional
unrelated affected families, allowing us to phenotypically
define this new ocular systemic disorder, which we call
ROSAH syndrome. ROSAH syndrome is named due to the
predominant features in affected individuals including retinal
dystrophy, optic nerve edema, splenomegaly, anhidrosis, and
migraine headache. Utilizing different genomic technologies
and analysis pipelines, we link the disease-causing variant in
ALPK1 (ɑ-kinase 1 [MIM 607347], c.710C>T, [p.Thr237Met])
to ROSAH syndrome in all five families. ALPK1 is a member
of a class of atypical protein kinases and our cellular,
expression, and functional studies suggest a critical role in
centrosome and cilia biology. This study defines the genetic
cause of ROSAH syndrome.
MATERIALS AND METHODS
The study protocol at the University of Utah for phenotyping
and analysis of patients in the Utah, Virginia, and Delaware
cohorts was approved by the Institutional Review Boards of
the University of Utah. The Australian patients were enrolled
in a research project approved by the ethics committee of The
Children’s Hospital at Westmead, Sydney Children’s Hospital
Network, Sydney, Australia. The patient from the Netherlands
was examined in a diagnostic setting. These projects conform
to the Declaration of Helsinki, and written, informed consent
was obtained from all participants and from the parents of
minors.
All study subjects underwent complete ophthalmic and
systemic examinations as dictated by the clinical needs of
each. Unaffected subjects also received a complete exam for
the purpose of phenotyping, and examination locations are
detailed in Supplementary Methods: Clinical Examination
Locations. For all families, whole blood was obtained and
genomic DNA was extracted from peripheral lymphocytes
according to previously described protocols.4–6
Exome sequence analysis: family 1 (Utah)
Exome sequencing was performed at the University of Utah
on four members of the Utah cohort: the proband (III-4, in
family 1, Fig. 1a), her unaffected sister (III-5), her affected
mother (II-3), and her unaffected father (II-4).
After exome sequence alignment and processing (Supple-
mentary Methods) the exome data of the family quartet was
analyzed using VAAST (v2.0) (ref. 7) by comparing the
exomes of the affected mother and daughter with a control
data set consisting of 54 genomes from the Complete
Genomics Diversity Panel8 and 1057 nonduplicative exomes
from the phase I release of the 1000 Genomes Project.9 The
analysis was restricted to the subset of variants that were
present in affected mother and daughter and absent in the
father and unaffected daughter. Given the extreme nature of
the phenotype and rarity of the disease, all variants in our
control data set and in the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project (ESP) were
excluded. The initial analysis resulted in a set of 44
candidate genes and none of the identified variants were
located in genes known to be associated with ocular diseases
such as retinitis pigmentosa or cone–rod dystrophy.
Variants that were predicted to cause severe changes in
protein function, were located in genes known to be
expressed in retina and spleen, or were located in genes
located in pathways not likely to be lethal were given highest
priority. After this analysis, of 23 potential disease-causing
variants, 5 were sequencing artifacts and of the others, only
the ALPK1 variant segregated appropriately with disease.
The ALPK1 variant was confirmed as a de novo pathogenic
variant in the proband’s mother (family I, II-3, Fig. 1a),
using the following primers: forward primer 5′-GGCAAA-
TAGTTCATATGGAGGAA-3′ and reverse primer 5′-
CCTCCCAATCTCCTGAGAAA-3′.
Genome sequence analysis: family 2 (Australia)
Independent genome sequencing was performed for all nine
members of the Australian cohort (family 2, Fig. 1a). After
genome sequence alignment and processing (Supplemen-
tary Methods) a variant call list was generated. Phen-Gen10
was used for post–variant call analysis. Phen-Gen incorpo-
rates disease symptoms to use the phenotype to genotype link
to improve the likelihood of novel disease gene identification.
Phen-Gen discards common variants (minor allele frequency
[MAF] >1% in dbSNP, 1000 Genomes, or ESP) and estimates
the deleterious impact of pathogenic variants, allowing for a
direct comparison of putative damaging variants across
different classes (nonsynonymous, splice site, and indels). It
further prioritizes the candidate gene list based on patient-
specific symptoms by integrating available disease knowledge
of phenotypically similar disorders, the genes implicated for
them, and other functionally similar genes. Symptoms listed
in Table 1 were used in the analysis. There were two candidate
variants suggested by the analysis, but one was of low
genotype quality and did not validate with Sanger sequencing.
Mutation validation of the ALPK1 pathogenic variant and
segregation with disease was shown by Sanger sequencing in
all family members (Macrogen Inc., Seoul, Korea) with the
following primers for ALPK1 (NM_001102406): forward 5′-
TGATCCTTCAAGCTCTGTGGC-3′, and reverse 5′-CCACC
AAGGACACGATTGACA-3′.
Exome sequence analysis: family 3 (Netherlands)
Diagnostic exome sequencing was performed in the proband
and his parents in the Netherlands cohort. After exome sequence
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alignment and processing (Supplementary Methods) variants
were filtered with the Cartagenia software package on quality
(read depth ≥10), MAF (≥0.1% in 200 alleles in dbSNP,
ESP6500, 1000 Genomes Project, GoNL, or ExAC), location
(within an exon or first/last 3 bp of introns). Subsequently
variants were further selected based on three inheritance
models (de novo autosomal dominant, autosomal recessive,
and X-linked recessive). Only variants predicted to change the
protein sequence (nonsynonymous single-nucleotide variants
and short insertions and deletions) or in the recognition of
consensus RNA splice sites were considered. Ninety-six
percent of the RefSeq sequences were covered at least 10×.
Confirmation of the ALPK1 variant was performed by Sanger
sequencing as described for the Utah family.
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Sanger sequencing: families 4 and 5 (Virginia and
Delaware)
Identification of the ALPK1 variant was performed in the
Virginia and Delaware families at the University of Utah by
Sanger sequencing using the primers as described for the Utah
family.
Alpk1 expression in the mouse
Mouse studies were approved by the Animal Care and Ethics
Committee of the Children’s Medical Research Institute,
Sydney, Australia. Alpk1 (NM_027808.1) expression was
examined in ARC(S) mouse female adult tissue and postnatal
(P) mouse retina. RNA was extracted from samples collected
from P5, P10, and adult tissues using RNeasy Lipid Tissue
Mini Kit (Qiagen, Australia). Complementary DNA (cDNA)
synthesis was performed using SuperScript III First-Strand
Synthesis SuperMix kit (Life Technologies, Australia) accord-
ing to manufacturer’s instructions. Reverse transcription
polymerase chain reaction (RT-PCR) was performed using
Biomix Red (Bioline, Australia) using the following primers:
forward 5′-GCAAGTGCTGGATCGTCTCT-3′ and reverse
5′-TTGTTTGTATTGCCACTTTTCAGG-3′.
ALPK1 expression in human tissues
ALPK1 messenger RNA (mRNA) expression was examined
via quantitative real-time PCR in human donor eye tissue as
well as in formalin-fixed, paraffin embedded (FFPE) spleen
tissue from two affected individuals from the Utah family
(family 1, II-3 and III-2) along with two age-matched
controls. Total RNA was extracted from macula retina and
retinal pigment epithelium (RPE)/choroid, extramacula retina
and RPE/choroid, and optic nerve from two normal human
donor eyes using the Qiagen All-Prep Kit (Qiagen, USA). The
resulting RNA was pooled for each tissue type. Total RNA
was isolated from archived FFPE spleen tissue using the
Qiagen All-Prep DNA/RNA FFPE kit (Qiagen, USA). cDNA
was synthesized using the iScript cDNA Synthesis Kit (Bio-
Rad, USA) following the manufacturer’s protocol. Real-time
PCR was performed using a predesigned ALPK1 PrimePCR
gene expression assay (Bio-Rad, USA). ALPK1 expression
data was normalized to the geometric mean of three
endogenous control genes (HSP90AB1, PPIA, and PSMC4),
which were experimentally validated to be stably expressed in
the tissue types evaluated. The resulting normalized
expression data was analyzed using the comparative Ct
(ΔΔCt) method.
Cell culture and immunocytofluorescence
Primary human fibroblasts were established from the skin
biopsy of affected and unaffected family members from the
Australian family (Fig. 1a, family 2), and cultured in
Dulbecco's Modified Eagle Medium (DMEM, Gibco) with
10% fetal calf serum, and 2-mercaptoethanol. ARPE19 cells
were maintained in DMEM with 10% fetal calf serum. To
enhance visualization of the primary cilium, serum starvation
for 24 hours was undertaken.11 For centrosome and cilia
analysis, human fibroblasts and ARPE19 cells were fixed in
methanol in −20°C. HeLa cells were maintained in Roswell
Park Memorial Institute medium (RPMI, Gibco) with 10%
fetal calf serum. For multinucleation analysis, HeLa cells were
transfected with GFP-ALPK1 (WT), GFP-ALPK1 (c.710C>T,
[p.Thr237Met]), or GFP-only vector (empty vector) using
Lipofectamine 2000 (Thermo Fisher Scientific, cat
#11668019), and untransfected HeLa cells were also used as
a control. The cells were fixed with 4% paraformaldehyde for
10 minutes 48 hours post-transfection. For centrosome, cilia,
and multinucleation studies, after washing the coverslips with
PBT (0.1% Tween 20 in phosphate-buffered saline) cells were
blocked in CAS-Block (Life Technologies, Australia, cat
#008120) and incubated at 4 °C overnight with primary
antibodies (Supplementary Table S1). Cells were incubated
with appropriate secondary antibodies (Supplementary
Table S1) for 2 hours at room temperature. Images were
captured using a Zeiss LSM 880 laser scanning microscope
with Airyscan. Super-resolution images were captured using
63×/1.4 Oil Plan-Apochromat objective and processed using
Zeiss ZEN Black software. For ciliation and multinucleation
studies, data were obtained from three independent replicates
where 100 cells were examined for each sample in each
experiment. Statistical analysis of the results was performed
using one-way analysis of variance (ANOVA) (GraphPad
Prism software) and p values were calculated by the two-tailed
t test.
Immunohistofluorescence
Adult female ARC(S) mouse eyes were collected, and the
corneas were removed. The eyes were embedded in optimal
cutting temperature compound (Tissue-Tek, cat #4583) and
Fig. 1 Pedigree of families with ROSAH syndrome and pathogenic variant identification in ALPK1. (a) Five families affected by autosomal
dominant ROSAH syndrome were analyzed in this study, from Utah (USA), Australia, The Netherlands, Virginia (USA), and Delaware (USA). Affected
individuals are shaded and those examined by exome sequencing and genome sequencing in the Utah, Australia, and Netherlands families are indicated
with an asterisk. Variant status is indicated below each individual for whom sequencing data was obtained (T237M indicates allele coding for [p.
Thr237Met]; + indicates normal allele). (b) Subsequent Sanger sequencing in all families confirmed segregation of the ALPK1 (NM_025144) variant with
disease. All individuals with the variant in ALPK1 have the ROSAH syndrome phenotype. The c.710C base pair (bp) is indicated by the arrow, and the bp
710–711 CG dimer is indicated by the thickened line. (c) Exonic structure of ALPK1 (NM_025144) with the pathogenic variant on exon 9 identified in ROSAH
syndrome. (d) Protein structure of ɑ-kinase 1 showing the location of the pathogenic variant and the location of the known kinase region. (e) Comparison
across species for ALPK1 Thr237 and flanking sequences using multiple sequence alignment from UniProtKB/UniRef100 Release 2011_12 (14 December
2011) database. A high degree of conservation of the Thr237 amino acid in vertebrates is evident. Flanking sequences are also highly conserved. Shaded
areas represent consensus sequence. Red letters represent deviation from consensus.
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snap frozen in liquid nitrogen. The paws were collected and
fixed in 4% paraformaldehyde for 1 hour. Samples were then
placed in 20% sucrose followed by 30% sucrose and
embedded in optimal cutting temperature compound. Tissue
samples were sectioned at a thickness of 14 µm. The tissue
sections were blocked in a buffer consisting of 0.1% fish
gelatin (Sigma Aldrich, cat #G7765), and 0.02% Triton X-100
in phosphate-buffered saline for 1 hour. Tissue sections were
incubated with primary antibodies (Supplementary Table S1)
overnight at 4 ºC, washed, and incubated with appropriate
secondary antibodies for 2 hours. Images were captured using
a Zeiss LSM 880 confocal microscope.
RESULTS
Clinical phenotype of ROSAH syndrome
There is marked similarity in the clinical features we
characterized in affected individuals from all five of these
unrelated families (Fig. 1a, Table 1, Fig. 2). We propose the
name ROSAH syndrome (retinopathy, optic nerve edema,
splenomegaly, anhidrosis, and migraine headache), due to the
consistency of the ophthalmic, hematologic, and systemic
signs, and detailed clinical case reports are provided in the
Supplementary Clinical Information Appendix. The most
frequent earliest feature is decreased vision associated with
presence of optic nerve edema on ophthalmic examination,
evident as early as 4 years of age and present by age 12 years
in all of the cases identified so far (Tantravahi et al.,3 Table 1,
Fig. 2a, l). This is not associated with elevated intracranial
pressure. Low-grade ocular inflammation is common in
affected individuals, and does not resolve with steroid or other
forms of immunosuppression. Later in childhood or the
second decade of life, patients have increasing visual
impairment and most have abnormal cone function and later
loss of rod function (Fig. 2f). By the third decade of life, visual
dysfunction is severe with visual acuity ranging from counting
fingers to no light perception. In addition to the ocular
findings, patients generally have splenomegaly that may begin
in childhood or the second decade, and may eventually
require splenectomy. Hematological assessment shows
chronic mild pancytopenia, which may be exacerbated during
periods of viral or other infection. Peripheral smears
frequently show leukopenia with reactive lymphocytosis.
Bone marrow examination is normocellular with trilineage
hematopoiesis and relative erythroid hyperplasia. Affected
individuals also have anhidrosis. Headaches and migraine are
a frequent feature, often associated with episodic fever and
back pain. Mild renal impairment was present in some
members of family 2 (Fig. 1a), but is not a consistent feature
in all patients.
Heterozygous ALPK1 pathogenic variant identified in
individuals with ROSAH syndrome
Independent exome sequencing in four members of the Utah
cohort (family 1, Fig. 1a), three members of the Netherlands
family (family 3, Fig. 1a), and genome sequencing in all
affected and unaffected family members of the Australian
cohort (family 2, Fig. 1a) was conducted. Comparison of
variants, also conducted independently, between affected and
unaffected individuals led to the identification of a missense
change in ALPK1, (Chr. 4q25, c.710C>T, [p.Thr237Met])
(Fig. 1b–d) as the likely disease-causing variant in each of the
families. This variant arose de novo in the Utah (family 1) and
Netherlands (family 3) families, and comparison of available
haplotype data between the Utah and Australian (family 2)
families was not consistent with a recent shared common
ancestor for these two families. Two additional unrelated
families with ROSAH syndrome were identified (family 4
[Virginia] and family 5 [Delaware]), and affected members
were found to be heterozygous for the ALPK1, (c.710C>T, [p.
Thr237Met]) variant, which arose de novo in the Delaware
patient. All families were of non-Hispanic, Caucasian
ancestry. This same C to T transition in all five unrelated
families, affected the bp 710–711 CG dimer (Fig. 1b) and may
represent a hotspot for mutation due to uncorrected
spontaneous deamination of a methylcytosine to thymine,
which is a known source of mutation in humans.12
Bioinformatic analysis with PolyPhen-2 (ref. 13) (HumVar
score 0.953) predicted the ALPK1, (c.710C>T, [p.
Thr237Met]) variant to be probably damaging, and SIFT14
predicted it to be damaging. The variant was highly conserved
across species, with a PhastCons15 score of 0.986 (Fig. 1e), and
was absent from the population database gnomAD. The
Thr237 amino acid is in a region of poorly defined function in
the protein, N terminal to the ɑ-kinase domain (Fig. 1d).
ALPK1 expression in the RPE, photoreceptors, and other
tissues
To further evaluate the possible role of the ALPK1 variant in
this disease, expression levels of ALPK1 were assessed via
quantitative real-time PCR in human donor eye tissue as well
as in FFPE spleen tissue from two affected individuals (family
1, II-3 and III-2) along with two age-matched controls. All
donor eye tissue was processed at 6 hours or less postmortem
time as previously described.16 In the eye, ALPK1 expression
was evaluated in the optic nerve, macula, RPE, and
extramacular retina. Pooled RNA from two normal eyes was
reverse transcribed and real-time PCR was performed. The
resulting data demonstrates increased expression of ALPK1 in
the RPE and optic nerve compared with retina (Fig. 3a). Real-
time PCR performed on spleen tissue samples confirmed the
expression of APLK1 in the normal spleen (data not shown).
However, the quality of the RNA obtained from the FFPE
tissue was too low to effectively compare diseased tissue
samples with normal samples.
In the mouse retina, confocal microscopy showed that
Alpk1 localized to the region of the photoreceptors where the
basal bodies of connecting cilia are located and to the RPE,
with some additional distribution across the inner and outer
plexiform layers (Fig. 3b, c). In the connecting cilium region,
costaining with a pancentrin antibody17 indicated localization
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of Alpk1 to the basal body of the photoreceptor cilium and
adjacent centriole region (Fig. 3c–f). In mouse skin, Alpk1
was present in the sweat glands, especially in the myoepithe-
lial cells where there was colocalization with the myoepithelial
cell marker α-SMA (Fig. 3g–r). There was also broad
expression in other mouse tissues (Supplementary Figure S1).
ALPK1 subcellular localization in centrosomes, spindle
poles, and primary cilia
Our immunofluorescence studies on ARPE19 cells revealed
the localization of ALPK1 in the spindle poles at metaphase
(Fig. 4a–f), and in centrosomes of cells during interphase
(Fig. 4g–i). Furthermore, cells were serum starved for 24 hours
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and then stained with ALPK1 antibody and acetylated α-
tubulin, which is a marker for primary cilia. Super-resolution
confocal imaging showed the presence of ALPK1 in the base of
primary cilia (Fig. 4j–l). This suggested a possible role for
ALPK1 in centrosome biology, which is critical for mitotic
spindle pole assembly and primary ciliary assembly.18
Abnormal cilia function due to ALPK1 variant, p.Thr237Met
Given the centrosomal localization of ALPK1 and its presence
in the basal regions of the primary cilium and the photoreceptor
cilium, we hypothesized that the ALPK1 pathogenic variant,
p.Thr237Met, may affect ciliogenesis. The evaluation of
ciliogenesis in the Australian family revealed, on average, 40%
of the cells were ciliated in an unaffected control, while only
15% and 13% of the cells could assemble the primary cilium in
two affected individuals (p<0.05) (Fig. 4m, n). These findings
suggest that phenotypic features in this family may relate to
abnormalities of cilia–centrosomal function.19
Increased proportion of multinucleated cells due to ALPK1
variant, p.Thr237Met
In view of the presence of ALPK1 in the spindle poles of
mitotic cells, we considered that the variant in this gene may
affect cell division and cytokinesis. Transfection of HeLa cells
with p.Thr237Met ALPK1 compared with wild type, empty
vector, and untransfected revealed that cells transfected with
the mutant protein had a significantly higher number of
multinucleated cells (16%), compared with the cells trans-
fected with wild-type ALPK1 (3.7%) or empty vector (5.7%)
(p<0.01) (Supplementary Figure S2).
DISCUSSION
We define a phenotypically distinct autosomal dominant
retinal dystrophy syndrome, ROSAH, with features of
retinopathy, optic nerve edema, splenomegaly, anhidrosis,
and headache in five unrelated families, and show hetero-
zygous (c.710C>T, [p.Thr237Met]) ALPK1 as the causative
variant in all cases. Some patients also exhibit low-grade
ocular inflammation and recurrent infections. Three inde-
pendent exome and genome sequencing family studies led to
the identification of this ALPK1 variant, which was confirmed
in the two additional families. The occurrence of the same
c.710C>T transition in a CG dimer in all five families
indicates the existence of a mutational hotspot. ALPK1 is an
ɑ-protein kinase of poorly defined function. Consistent with
the phenotypic features in our patients, we showed that
ALPK1 was highly expressed in retinal tissues, notably the
retinal pigment epithelium and the connecting cilium region
of photoreceptors, localized to myoepithelial cells of sweat
glands, and was expressed across most other tissues. Our
cellular investigations suggest a role for ALPK1 in centroso-
mal cilia function. Our findings show that ROSAH syndrome
is a distinctive autosomal dominant retinal dystrophy
syndrome, caused by a recurrent heterozygous variant in
ALPK1, and indicate a role for ALPK1 across several different
organ systems.
ALPK1 was first identified as a member of a family of
atypical protein kinases, the ɑ-kinases, through homology to
the catalytic domain of myosin heavy chain kinase.20 These
kinases phosphorylate sites that are surrounded by peptide
regions with ɑ-helical secondary structure.21 The ALPK1
catalytic domain lies between amino acids 1027 and the
carboxy-terminus at 1244 (Fig. 1d).22 It has homology to the
myosin heavy chain kinase of Dictyostelium.20 In addition,
ALPK1 has been shown to phosphorylate myosin 1a in
MDCK cells.23 In MDCK cells, ALPK1 has been shown to
play a role in trafficking sucrose–isomaltase lipid rafts from
the Golgi network through phosphorylation of myosin 1a.23,24
Fig. 2 Clinical images for patients III.2 and II.3 from the Australian cohort and II.1 from the Delaware cohort.(a–d) Fundus imaging for patient III.2,
Australian cohort. (a) Swollen optic disc with swelling extending onto the peripapillary nerve fiber layer. (b) Fundus image showing the vitreous and
preretinal hemorrhage. (c) Ultrawide field fundus images color corrected with Optos viewing software (Optos plc, Dunfermline, Scotland, UK) shows
prominence of the nerve fiber layer, early retinal atrophy particularly just anterior to the vascular arcades. No pigmentary changes are seen. (d) Ultrawide
field fundus autofluoresence (FAF) (Optos plc, Dunfermline, Scotland, UK) showing diffuse hyperautofluoresence in a broad ring extending anterior to the
vascular arcades and loss of the normal foveal hypoautofluorescence. (e, g) OCT. (e) Patient III.2 from Australian cohort shows retinal and peripapillary
generalized thickening with indistinct retinal layers. The macula shows cystic changes and loss of the external limiting membrane (ELM) and photoreceptor
inner segment/outer segment (IS-OS) junction. (g) Age-matched normal OCT is shown for comparison. (f, h) Visual electrophysiology. (f) Patient III.2 from
the Australian cohort shows moderate photoreceptor dysfunction involving both the rod and cone systems. The DA 3.0, 30-Hz flicker, and LA 3.0 have b-
wave amplitudes reduced to 50% of normal. The DA0.01 has blink artifact affecting interpretation. The pattern ERG (assessing macular function, not
shown) was extinguished for the 15° field responses. The combination of electrophysiology results, OCT loss of ellipsoid zone, and reduced visual acuity led
to classification as a cone–rod pattern of dysfunction. (h) Normal age-matched ISCEV standard ERG recordings are shown for comparison. These illustrate
normal amplitudes and latencies for the scotopic (rod dependent system) DA 0.01, DA 3.0, and DA 12.0, and photopic (cone dependent system) 30-Hz
flicker and LA 3.0. (i–k) OCT and fundus imaging for patient II.3, Australian cohort. (i) OCT shows thickening of the retina with loss of the normal retinal
layer reflectance pattern and vitreous condensation (band) attaches to an epiretinal membrane. (j) The standard 50° fundal retinal image shows optic
atrophy, marked retinal vascular attenuation, and pigmentary retinopathy. There is significant vitreous condensation overlying the retina obscuring some
detail. (k) Ultrawide field image highlighting the extent of the pigmentary changes, which extend to the equator. (l) OCT retinal nerve fiber layer (RNFL),
patient II.1 from the Delaware cohort, showing optic nerve edema and thickening of the peripapillary retinal nerve fiber layer (arrows). (m) Macula OCT,
patient II.1 from the Delaware cohort, showing thickening of retina and reduction of the retinal lamination reflectance layers. (n) Goldmann visual fields (left
and right), patient II.1 from the Delaware cohort, showing constriction of visual fields. OCT, Optical coherence tomography; ERG, Electroretinogram; ISCEV,
International Society for Clinical Electrophysiology of Vision; DA, Dark adapted; LA, Light adapted; Hz, Hertz; ms, Millisecond; Div, division; TMP, Temporal;
SUP, Superior; NAS, Nasal; INF, Inferior; RNFLT, Retinal nerve fiber layer thickness.
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Fig. 3 ALPK1 expression in pooled normal human ocular tissues, mouse retina, and mouse sweat glands. (a) Quantitative real-time polymerase
chain reaction (PCR) data, normalized to the geometric mean of HSP90AB1, PPIA, and PSMC4, shows increased expression of ALPK1 in the RPE and optic
nerve tissue relative to macula retina tissue. Error bars represent the standard deviation of expression in technical replicates. (b–f) Alpk1 expression in the
retinal pigmented epithelium and photoreceptor cells. (b) Adult mouse retinal section stained with anti-Alpk1 (green, MyBioSource, cat #MBS001969), and
DAPI (blue) shows expression of Alpk1 in the RPE and connecting cilium region of the photoreceptor cells. (c–e) Magnification of the RPE and photoreceptor
layers. Centrin (red) is a pancentrin antibody that marks the connecting cilium, basal body, and adjacent centriole of the photoreceptor. The merged image
shows the localization of Alpk1 to the basal body region of the photoreceptor cilium and the region of the adjacent centriole. (f) Magnification of the
connecting cilium region. (g–r) Expression of Alpk1 in mouse sweat glands: immunostaining of mouse paw sweat glands with (g) DAPI labeling the nuclei of
cells in the skin of the mouse paw; (h) anti-Alpk1 antibody (green, Proteintech, cat #19107-1-AP); (i) anti-ɑ smooth muscle actin (α-SMA, red) as a
myoepithelial cell marker. (j) Merged image of three channels indicates the high expression of Alpk1 in myoepithelial cells of sweat glands. (k) Stacked
image of multiple layers of the sweat gland with 0.5-μm Z-level using confocal microscope. (l) Mouse sweat gland histology illustrating the morphology
and location. (m–r) Magnified regions of the sweat glands encompassed by the box in (k) and (l). Scale bars represent 50 μm in (b) and (k), and 10 μm in
(c–e) and (q). CC connecting cilium, GC ganglion cell layer, INL inner nuclear layer, IPL inner plexiform layer, IS inner segment of photoreceptors, ONL outer
nuclear layer, OPL outer plexiform layer, OS outer segment of photoreceptors, RPE retinal pigmented epithelium.
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When disrupted, ALPK1 regulation of apical transport may
affect cellular establishment of polarity.24
In all patients with ROSAH syndrome there is evidence of
an early-onset retinal dystrophy. We noted presence of Alpk1
in the basal region of the connecting cilium of the
photoreceptors (Fig. 3b–f), as well as the centrosomes and
base of the primary cilium (Fig. 4a–l). We identified reduced
ciliation of fibroblast cells from patients affected with ROSAH
syndrome compared with controls. Pathogenic variants in
centrosome–cilia proteins have been extensively described in
syndromic and nonsyndromic forms of retinal dystrophy
disease, such as pathogenic variants in TOPORS, RPGR,
RP2, CC2D2A, and CEP290 (refs. 25–30). These pathogenic
variants indicate that ciliary–centrosomal abnormality is one
of the known pathways that contributes to the pathogenesis of
retinal dystrophy through defects in ciliary formation and
regulation of cargo trafficking in the photoreceptors.19 In
addition, cilia formation is linked with cell cycle progression31
and localization of ALPK1 at the spindle poles during mitosis
(Fig. 4a–f) raises the possibility that abnormality of ALPK1
may impact cell cycle progression, another factor that may
contribute to a retinal degeneration phenotype.32 Noting that
the population database gnomAD did not reveal likely loss-of-
function intolerance of ALPK1, we investigated the impact of
overexpression of ALPK1 (c.710C>T,[p.Thr237Met]) in HeLa
cells and showed increased multinucleated cells (Supplemen-
tary Figure S2), suggesting a possible gain-of-function disease
mechanism. ALPK1 was also expressed in the RPE where its
role in maintenance of epithelial cell polarity may also be
important for normal function of the RPE and prevention of
retinal dysfunction. Patients with ROSAH syndrome also
exhibited anhidrosis, so the role of ALPK1 in maintenance of
epithelial cell polarity may also be relevant for normal
function of the sweat glands.
There are several reports of proposed association of single-
nucleotide polymorphisms (SNPs) in ALPK1 with increased
susceptibility to inflammatory conditions, including gout and
chronic kidney disease.33,34 In the mouse, Alpk1 was found to
mediate innate immune responses to bacterial infection35 and
Alpk1 abnormality was found to be associated with increased
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Fig. 4 ALPK1 localization to the centrosomes and base of the cilia in cells and the impact of ALPK1 (c.710C>T, [p.Thr237Met]) variant on
primary cilia assembly. (a–c) Antibody staining of fixed ARPE19 cells with anti-ALPK1 (green, Proteintech, cat #19107-1-AP) and anti-α-tubulin (red)
antibodies in a mitotic cell shows the localization of ALPK1 in spindle poles. (d–f) Further immunostaining of ARPE19 cells with anti-γ-tubulin (red) confirmed
the centrosomal localization of ALPK1 during mitosis. (g–i) Localization of ALPK1 in ARPE19 cells in interphase shows a diffuse cytosolic pattern and
enrichment of ALPK1 in centrosomes of the cells, which colocalize with γ-tubulin. (j–l) ARPE19 cells were serum starved for 24 hours and immunostained
with anti-ALPK1 (green, Proteintech, cat #19107-1-AP) and anti-acetylated-α-tubulin (red) showing the ALPK1 localization at the base of primary cilium. Cell
nuclei are stained with DAPI (blue). (m) Fibroblast cells were treated with serum-free medium for 24 hours and labeled with primary cilia markers anti-
acetylated-α-tubulin (red), anti-IFT88 (green), and DAPI (blue). Representative images of unaffected cells and affected cells carrying ALPK1 (c.710C>T,
[p.Thr237Met]) variant show decreased number of ciliated cells in fibroblasts from affected patients compared with control. (n) Quantification of the ciliated
cells in one unaffected control and two affected patients. The analysis showed significant decrease in assembly of primary cilia in the affected patients
carrying ALPK1 (c.710C>T, [p.Thr237Met]) variant. The graphs show the means ± s.e.m. from three independent experiments where 100 cells were scored
for each sample in each experiment. *p<0.05. Scale bars represent 5 μm in (a, d, g, j) and 10 μm in (m, n).
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susceptibility to inflammatory bowel disease.36 The role of
ALPK1 in inflammation may be mediated through regulation
of NF-κB signaling.37 Interestingly, the N terminal region of
ALPK1, including the Thr237 amino acid affected in our
patients, has been found to be critical for stimulation of the
ALPK1 kinase domain and phosphorylation and activation of
downstream targets in the NF-κB signaling pathway.35
Patients with ROSAH syndrome also show signs of
inflammation, exhibiting recurrent or chronic low-grade
uveitis, although the uveitis does not appear to be clinically
alleviated by immunosuppression. Abnormalities of the innate
immune pathway may also contribute to retinal degeneration,
raising a further avenue for investigation in ROSAH
syndrome patients. Some patients with ROSAH syndrome
also exhibit episodic infections, fevers, and pancytopenia,
further indicating an inflammatory component to this
condition.
Our report is the first where a pathogenic variant in ALPK1
is found in affected individuals with Mendelian disease. Motor
coordination deficits of unknown mechanism have been
found in mice with the catalytic domain of ALPK1 disrupted
by a piggyBAC transposon.38 None of the individuals in the
families we describe have motor coordination defects. These
mice and the Alpk1 loss-of-function mice with inflammatory
abnormalities were not tested for blindness or retinal
dystrophy.35,36 The etiology of the optic nerve edema,
splenomegaly, and headache is unclear in ROSAH syndrome
patients. Two patients had lumbar punctures performed due
to concerns about raised intraocular pressure because of the
appearance of the optic nerve head, but no increased pressure
was detected. ALPK1 may be important in the development of
the red blood cell (RBC) cytoskeleton, which if impaired may
lead to the propensity to form elliptocytes noted in one case,
and may be filtered at the level of the spleen resulting in
splenomegaly. In addition, our patients exhibit headache,
which has been associated with alterations in kinase function
affecting calcitonin gene related peptide and trigeminal nerve
pain.39,40
In summary, we name this autosomal dominant condition
ROSAH syndrome to reflect the most common features across
affected individuals: retinopathy, optic nerve edema, spleno-
megaly, anhidrosis, and headache, and identify p.Thr237Met
ALPK1 as the causative variant. Future studies are warranted
to examine the precise pathophysiological mechanism of this
new autosomal dominant retinal dystrophy syndrome.
URLS
1000 Genomes, http://www.internationalgenome.org/; dbSNP,
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www.broadinstitute.org/igv/; MutationTaster, http://www.
mutationtaster.org/; NCBI Genome, http://www.ncbi.nlm.nih.
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nuccore/; NCBI Primer designing tool, https://www.ncbi.nlm.
nih.gov/tools/primer-blast/; NHLBI Exome Sequencing Pro-
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